



(12) **United States Patent**
Hooper et al.

(10) **Patent No.:** **US 7,790,182 B2**
(45) **Date of Patent:** **Sep. 7, 2010**

(54) **PROTEIN VACCINES AGAINST POXVIRUSES**

(75) Inventors: **Jay W. Hooper**, New Market, MD (US);
Genoveffa Franchini, Washington, DC (US)

(73) Assignee: **The United States of America as represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 177 days.

(21) Appl. No.: **11/523,867**

(22) Filed: **Sep. 20, 2006**

(65) **Prior Publication Data**

US 2010/0196491 A1 Aug. 5, 2010

Related U.S. Application Data

(60) Provisional application No. 60/722,082, filed on Sep. 21, 2005.

(51) **Int. Cl.**

A61K 39/275 (2006.01)

A61K 39/285 (2006.01)

A61K 31/7088 (2006.01)

(52) **U.S. Cl.** **424/232.1**; 514/44 R

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,340,463	B1	1/2002	Mitchell et al.	424/263.1
6,451,309	B2	9/2002	Hooper et al.	424/147.1
6,562,376	B2*	5/2003	Hooper et al.	424/489
6,620,412	B2	9/2003	Hooper et al.	424/147.1
6,630,144	B1	10/2003	Hart et al.	424/159.1

FOREIGN PATENT DOCUMENTS

WO WO 00/00617 1/2000

OTHER PUBLICATIONS

Doria-Rose et al (Methods 31: 207-216, 2003).*

Shchelkunov et al (Virology 297:172-194, 2002).*

CDC Smallpox Response Plan. Executive summary. Mar. 20, 2003. Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA.*

CDC Monkeypox Guidelines and Resources. Jun. 25, 2003. Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA.*

Hooper et al (Journal of Virology 78:4433-4443, 2004, cited in IDS).*

Heraud et al (Journal of Immunology 177:25552-2564, 2006, not prior art, cited in IDS).*

Aldaz-Carroll, et al., "Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5R", J. Virology, vol. 79, No. 10, May 2005, pp. 6260-6271.

Boyce et al., "Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children", Vaccine 18 (2000), pp. 82-88.

Chakrabarti et al., "Compact, synthetic, vaccinia virus early/late promoter for protein expression", Short Technical Reports, Biotechniques, vol. 23, No. 6, 1997, pp. 1094-1097.

Chen et al., "Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus", PNAS, Feb. 7, 2006, vol. 103, No. 6, pp. 1882-1887.

Czerny and Mahnel, "Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies", J. General Virology (1990), vol. 71, pp. 2341-2352.

Fang et al. "Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host", Virology 345 (2006), pp. 231-243.

Fenner, "Poxviruses", chapter 84, Fields Virology, 3rd ed., Lippincott-Raven Publishers, Philadelphia, 1996, pp. 2673-2702.

Fogg et al., "Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions," J. Virology, vol. 78, No. 19, Oct. 1994, pp. 10230-10237.

Demkowicz et al., "Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans", J. Virology, vol. 66, No. 1, Jan. 1992, pp. 386-398.

Earl et al., "Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox," Nature, vol. 428, Mar. 2004, pp. 182-185.

Edghill-Smith et al., "Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge", JID 2005:191 (Feb. 1), pp. 372-381. Edghill-Smith et al., "Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus", Nature Medicine, vol. 11, No. 7, Jul. 2005, pp. 740-747.

Edghill-Smith et al., "Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques", JID 2003:188 (Oct. 15), pp. 1181-1191.

Engelstad et al., "A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope", Virology 188, pp. 801-810 (1992).

Esposito et al., "Genome sequence diversity and clues to the evolution of variola (smallpox) virus", Science, vol. 313, Aug. 11, 2006, pp. 807-812.

Galmiche et al., "Neutralizing and protective antibodies directed against vaccinia virus envelope antigens", Virology 254, (1999), pp. 71-80.

Gordon et al., "A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope", Virology 181, (1991), pp. 671-686.

(Continued)

Primary Examiner—Mary E Mosher
(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57) **ABSTRACT**

The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins.